Although the benefit of SGLT2i and GLP-1 RA is consistent for all patients with kidney disease and diabetes, some subgroups with specific levels of GFR and albuminuria-proteinuria are underrepresented in major clinical trials. This evidence concerns the gene GLP1R and kidney disorder.